Slide 1: Owlet, Inc. Q3 2025 Financial Results
Owlet, Inc. (NYSE: OWLT) Q3 2025 Financial Results November 13, 2025 March 4, 2025 1
Slide 2: Conference Call
Owlet, Inc. (NYSE: OWLT) | Q3 2025 Financial Results Conference Call Speakers ● Jonathan Harris, CEO & President ● Amanda Twede Crawford, CFO ● Jay Gentzkow, VP Investor Relations and Corporate Development Webcast ● Domestic Callers: (833) 470-1428 ● International Callers: (646) 844-6383 ○ Access Co
Slide 3: Disclaimer
Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this presentation that do not relate to matters of historical fact should be consider
Slide 4: Owlet Business Update
Owlet Business Update Confidential | 4
Slide 5: Owlet Business Update | Third Quarter 2025
Owlet Business Update | Third Quarter 2025 Record Revenue Gross Margin Record Adj. EBITDA $32.0M 50.6% $1.6M Growth of 44.6% y/y Record quarterly Improved $1.0M y/y Gross Profit of $16.2M Operating Income Profitable Business Highlights ● Q3ʼ25 financial performance exceeded expectations across all k
Slide 6: First and Only FDA-Cleared Pediatric Health Monitor on the Market with Significant Barriers to Entry
First and Only FDA-Cleared Pediatric Health Monitor on the Market with Significant Barriers to Entry With years of effort & significant investment, Owlet meets rigorous standards for clinical efficacy and safety with FDA clearance Note: FDA-cleared via the De Novo pathway. Confidential | 6
Slide 7: Strategic Focus Areas for Growth
Strategic Focus Areas for Growth Core Domestic International Owlet360 Healthcare Growth Growth Subscription Expansion ● Continued execution on core ● New regulatory clearances and ● Owlet360 unlocking and ● Long-term opportunity for domestic product growth certifications, and channel monetizing mass
Slide 8: Financial Highlights
Financial Highlights Confidential | 8
Slide 9: Financial Review | Q3 2025
Financial Review | Q3 2025 Revenue Gross Margin ● Record $32.0M Q3ʼ25 revenue ● 50.6% Q3ʼ25 gross margin ● 44.6% growth y/y ● Record quarterly gross profit of $16.2M $ in millions Confidential | 9
Slide 10: Financial Review | Q3 2025
Financial Review | Q3 2025 Operating Expenses Adj. EBITDA ● $15.0M Q3ʼ25 total operating expenses ● Record $1.6M Q3ʼ25 adj. EBITDA ● OpEx as a percentage of revenue was 47% vs. ● First quarter of positive Operating 74% in Q3ʼ24 Income – $1.2M $ in millions $ in millions Note: Adjusted EBITDA is defi
Slide 11: Updating FY 2025 Guidance
Updating FY 2025 Guidance Previous New 2025E Guidance Guidance Revenue $97M – $100M $103M – $106M 32-36% growth y/y Including new, increased Gross Margin 46% – 50% 48% – 50% tariff costs Fully expect to $3.1-$3.8M improvement Adj. EBITDA $1.25M – $2M be positive vs. FY 2024 Note: Adjusted EBITDA is d
Slide 12: Q&A
Q&A Confidential | 12